Maria Jiang

We keep rediscovering the same truth—hormonal biology works. Estrogen returns in prostate cancer, this time via patches, with noninferior outcomes and potentially better tolerability. Not new—just better applied. Study in @NEJM by the #Stampede group/@MRCCTU nejm.org/doi/full/10.10…

ctDNA data for radiotherapy (TMT) in muscle invasive bladder cancer shows 19/59 pts (32%) were ctDNA+ve at baseline (⬇️ than in NIAGARA 57%). 11/19 had ctDNA clearance with TMT. Those that didn’t clear had ⬆️ risk of systemic rather than local relapse, underlining TMTs role in local rather than systemic control. CtDNA helps. Congrats to the team. @OncoAlert

⚡️ ctDNA after bladder-sparing trimodality therapy in MIBC. In 84 patients treated with chemoradiotherapy, detectable post-CRT plasma ctDNA strongly correlated with metastatic recurrence, but not with isolated local relapse. Supports ctDNA as a marker of distant relapse risk. @CCR_AACR #BladderCancer #ctDNA #MIBC aacrjournals.org/clincancerres/…

Perioperative Enfortumab Vedotin and pembrolizumab beats neoadjuvant chemotherapy & cystectomy in muscle invasive bladder cancer. We’re moving towards a bladder surgery sparing strategies using EVP. This is another step towards curing bladder cancer pfizer.com/news/press-rel…

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery

Pleased to present at #ESMO25 the 16 year experience of tandem high-dose chemotherapy and autologous stem cell transplant for relapsed/refractory advanced stage germ cell tumours from @pmcancercentre .

The AlphaBet trial @PeterMacCC @TheLancetOncol release today @myESMO #ESMO25: combining Lu-177 PSMA-I&T + Ra-223 in men with metastatic castration-resistant #ProstateCancer is safe, feasible, and active. ✅ No dose-limiting toxicities 💪 PSA-50% decline in 55% 🧬 Supports future α+β theranostic combos. 🔗 authors.elsevier.com/a/1lyc65EIIgTS… Congrats @LouiseKostos: what an amazing PhD! Thank-you to @PCF_Science @pros_tic @Bayer for funding & support, co-senior author @AzadOncology, all the co-authors, wider village of contributors and most importantly our patients and their families for participating.

🚨Just in @NatureMedicine 👉 results from the Ph 3 AMPLITUDE trial: adding niraparib to abiraterone ⬆️outcomes in HRR-altered mHSPC #prostatecancer 👉 RPFS ⬆️: BRCA 1/2 HR 0.52, P < 0.0001; ITT HR 0.63, P =0.0001 Open link👉 bit.ly/47lt5Oj @PCFnews @OncoAlert @urotoday

Five great UC studies #ESMO25 - 1/5 Disitimab Vedotin (HER2) +Toripalimab vs platinum chemo in 1st line HER2+ve UC is positive for PFS/OS. Press release says ‘This reshapes the global treatment landscape of UC,” which sounds v.good. Can it be better than EVP? Are sfx different?

📬 The Milan Consensus paper on Clinical CR definition & Endpoints for next-gen bladder-sparing trials is out in @JCO_ASCO @ASCO | following the @SanRaffaeleMI #GURetreat24 Co-sponsored by @IBCG_BladderCA @GTumors It was a tremendous multidisciplinary effort involving friends/KOL from various fields, pt advocates @BladderCancerUS @WorldBladderCan Pharma Industries & @FDA #EMA proving insights ✅ cCR should be rigorously based on imaging + biopsy + urinary citology ✅cCR still immature as primary endpoint for registration trials (good for esploratory studies) ✅ EFS good for registration trials ✅ EFS should capture ANY type of event including HG bladder relapses 🛜 role of biomarkers (ctDNA/utDNA) still to conceive in this clinical setting but likely to become the next 🧩 @MyUniSR @UroDocAsh @SpiessPhilippe @sonpavde #MattGalsky @#bladdercancer #endpoints #clinicalresearch @urotoday @OncLive @OncoAlert @Larvol

JUST IN: Tar200 now @US_FDA approved based on SunRise-1 phase 2 trial in BCG unresponsive NMIBC. -Intravesical form of Gemcitabine - CR: 82.4%/grade ≥3 AE 12.9% - DFS 70.2% at 12m - 51% of CRs with DOR ≥ 12 months.

Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… Population-based study in Ontario 🇨🇦evaluated factors influencing the use of treatment intensification in older men with de novo metastatic hormone-sensitive #ProstateCancer , finding that only 24% received additional therapy beyond androgen deprivation. Physician specialty significantly impacted treatment patterns, with patients managed by radiation oncologists less likely and those seen by medical oncologists more likely to receive intensification, while older age strongly decreased the likelihood of intensified therapy. These results highlight that both patient and physician characteristics drive variation in care, emphasizing the need for targeted interventions to improve uptake of guideline-recommended, life-prolonging therapies. @DavidDan_Ngn @DrRajSat @KhattiA @AHirdMD @Soum_Roy_RadOnc @DrMichaelOng @DiMariaJiang @drgotto @GSK_UofT @RodBreau @lalaniMD @WallisCJD @OncoAlert 🚨 @Silke_Gillessen @AOmlin @nataliagandur @bavilima

Congratulations Shilpa @shilpaonc and Ben @maughanonc for leading these efforts and congratulations to the team for this work in the prestigious @EUplatinum European Urology. @PGrivasMDPhD @EAntonarakis @bilenma @LiangChengMD @LDyrskjot doi.org/10.1016/j.euru…

IMVIGOR011: Atezo vs placebo in ctDNA+ve bladder ca (including -ve becoming +ve) post cystectomy hit OS/PFS. It also tracks outcomes in the ctDNA-ve, supporting a ctDNA adjusted approach. It’s been a long journey for atezo in UC but it has +ve OS at last natera.com/company/news/i…

Perioperative EVP shows ⬆️ EFS,OS & pCR vs cystectomy alone in high risk cisplatin ineligible MIBC (KN901). Highly active systemic vs surgery will rescue many patients with aggressive micrometastatic disease. CRs for EVP=30% in M1 but should be ⬆️ in MIBC biospace.com/press-releases…

Just came online in @TheLancet 👉Our two papers on improved OS with Enzalutamide + Talazoparib in mCRPC #ProstateCancer in all-comer & HRRm patients (Median OS and HRs👇). Weblinks to the papers👉 bit.ly/4lXkLtB and bit.ly/4nNIyOh @PCFnews @urotoday @OncoAlert

ctDNA can help guide adjuvant decision making in MIBC In pts with undetectable ctDNA after NAC + cystectomy, no definitive benefit for adjuvant ICB authors.elsevier.com/c/1lMET14kpm0h… @MattGalsky @TischCancer @IcahnMountSinai @Uromigos @BladderCancerUS @urotoday @WorldBladderCan @OncLive

#VIOLET Study of Terbium-161 (161Tb) - first trial of Beta/Auger therapy. Recently presented #ASCO25. Now out in @TheLancetOncol : thelancet.com/journals/lanon… 🟣 30 patient trial in prostate cancer. No dose limiting toxicities at highest level of radioactivity (7.4 GBq) 🟣Very few side effects: 1 grade 3 lymphopenia, 1 grade 3 pain exacerbation. No grade 4. No dose delays. 🟣 Completed >6 months ahead of schedule. Thanks @Isotopia_Global for just-in-time delivery of Tb-161 Huge team involved: @ButeauJames PhD, @AzadOncology medical oncology lead, @pj_physics physics lead, @LouiseKostos PhD, @MHaskali radiochemistry, many others 🟣Funding from @PCF_Science @pros_tic @PeterMacCC @Isotopia_Global 🟣🙏patients who participated, clinical trials team, nuclear medicine team

Congrats @MichaelOng_MD for the stellar talk @ASCO #ASCO25 👉 PSA response (<0.2 ng/ml) after starting ADT+ARPI in mHSPC #prostatecancer (occurred in 50% of pts) associated with ⬆️OS (& 5-fold ⬆️ in death if PSA is >\=0.2). @OncoAlert @urotoday @PCF_Science @Daniel_J_George

#News: Phase III PSMAddition trial demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. go.novartis.social/4jzLY42